We're leading the latest round in Formation Bio, an AI-native pharma company focused on drug development, arguably the consequential bottleneck in bringing new medicines to patients. Though AI has made drug discovery more and more efficient, the cost and time of clinical trials continues to get longer and more expensive. Drawing from their experience tackling this problem for the past decade, and through partnerships with companies like OpenAI and Sanofi, Formation Bio founders Benjamine Liu and Linhao Zhang are perfectly suited to build the next generation pharma company. More on why we invested:
Awesome! Neel Madhukar
Congrats!!
None of the above should be taken as investment advice or an advertisement for investment services; please see https://a16z.com/disclosures/ for more information.